SSR240600C Treatment in Women With Overactive Bladder

A Placebo Controlled Randomized, 12-week, Dose-ranging, Double-blind Study Versus Placebo Using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of SSR240600C in Women With Overactive Bladder Including Urge Urinary Incontinence

The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.

Inclusion Criteria:

• Diagnosis of overactive bladder

Exclusion Criteria:

• Stress incontinence or mixed incontinence where stress incontinence is the predominant component based on prior history
• Urinary incontinence due to cause other than detrusor overactivity (eg, overflow incontinence)
• Current Urinary Tract Infection (UTI) or frequent UTIs
• Urinary retention or other evidence of poor detrusor function
• Pain during voiding or bladder pain without voiding
• History of radiation cystitis or history of pelvic irradiation
• History of interstitial cystitis or bladder related pain syndrome

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.